Clinical trials: Cell Transplantation
Chemotherapy-induced Nausea and Vomiting
Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants
The purpose of this research study is to see if olanzapine helps to prevent nausea and/or vomiting (throwing up) when it is added to other medicines in subjects having stem cell transplants.
- Trial name
- NCT04535141
- Testing
- Olanzapine 5 MG
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Sarcoma
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with peripheral stem cell transplantation may allow…
- Trial name
- NCT00002601
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Conditions
- Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma
- Trial name
- NCT01267812
- Testing
- bortezomib, rituximab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- City of Hope Medical Center
Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
This phase I/II trial studies the side effects of laboratory-treated T cells and to see how well they work in treating patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous…
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT01640301
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Fred Hutchinson Cancer Center
Sickle Cell Disease
SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
Related donor stem cell transplantation using the alemtuzumab/ TBI platform has been shown to be a safe strategy to cure severe sickle cell disease.
- Trial name
- SCD-Haplo (NCT02013375)
- Testing
- Haploidentical Transplant, Alemtuzumab, Total Body Irradiation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Damiano Rondelli, MD
Hematologic Malignancy
Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies
This research study is studying the removal of a subset of white blood cells (called alpha/beta T cells) from the donor product using a cell separation device before the product is transplanted into the participant.
- Trial name
- NCT03717480
- Testing
- ClinicMACs
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Non-Hodgkin
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
- Trial name
- TRANSCENDWORLD (NCT03484702)
- Testing
- JCAR017
- Where
- 20 sites in Austria, Belgium and 9 more
- Volunteers
- 113 people
- Sponsor
- Celgene
Tracheal Diseases
Laryngo-Tracheal Tissue-Engineered Clinical Transplantation
The proposed protocol will involve the replacement of the trachea using a synthetic bioengineered scaffold seeded with autologous mononuclear cells as an intraoperative solution for patients with with benign and malignant…
- Trial name
- NCT01997437
- Testing
- Stem-cell seeded bioartificial tracheal scaffold
- Where
- Russia
- Volunteers
- 6 people
- Sponsor
- Kuban State Medical University
Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
This phase II trial studies how well sirolimus, cyclosporine and mycophenolate mofetil works in preventing graft-vs-host disease (GVHD) in patients with blood cancer undergoing donor peripheral blood stem cell (PBSC) transplant.
- Conditions
- Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, Adult Myelodysplastic Syndrome
- Trial name
- NCT01251575
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 5 sites in United States, Denmark
- Volunteers
- 77 people
- Sponsor
- Fred Hutchinson Cancer Center
Tick Borne Encephalitis
Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
Patients undergoing allogeneic blood and marrow transplantation (HSCT) experience a prolonged period of dysfunctional immunity. Systematic reimmunization is necessary at appropriate time intervals following transplantation to…
- Trial name
- NCT01991067
- Testing
- TBE virus vaccine
- Where
- Austria
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Multiple Myeloma
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
This randomized phase II trial compares how well adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant works in treating patients with multiple myeloma.
- Trial name
- NCT02112045
- Testing
- Granix, High dose melphalan (HDR), Autologous Stem Cell Transplant (ASCT)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Hematologic Malignancies
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
The purpose of this study is to determine if Velcade (also known as bortezomib) can help prevent graft versus host disease (GVHD) developing after transplantation.
- Trial name
- NCT00369226
- Testing
- Bortezomib (Velcade), Tacrolimus, Methotrexate
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Improve the Informed Consent Process
Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials (BMT CTN 1205)
The study has two parts: (1) Randomized Study to evaluate the effectiveness of ETRIC, and (2) Evaluation Study to understand barriers to implementation of ETRIC.
- Trial name
- NCT02081248
- Testing
- Consent Form Specific Format 1, Consent Form Specific Format 2
- Where
- 23 sites in United States
- Volunteers
- 198 people
- Sponsor
- Medical College of Wisconsin
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
This randomized phase III trial is studying total-body irradiation (TBI) and fludarabine phosphate to see how it works compared with TBI alone followed by donor stem cell transplant in treating patients with hematologic cancer.
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Aggressive Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00075478
- Testing
- Total-Body Irradiation, Fludarabine Phosphate, Mycophenolate Mofetil
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 87 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation
BEAM regimen (BCNU, etoposide, cytarabine, and melphalan) is the most commonly used conditioning regimen for relapsed/refractory lymphoma patients needing autologous stem cell transplantation.
- Trial name
- V-BEAM (NCT01653418)
- Testing
- Bortezomib, Carmustine, Etoposide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Herpes Zoster
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem…
- Trial name
- NCT00920218
- Testing
- Herpes Zoster Vaccine 1437173A
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- GlaxoSmithKline
Plasma Cell Myeloma, Plasmacytosis
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase I/II trial studies the safety and best dose of melphalan and bortezomib when given prior to an autologous stem cell transplant and to see how well they work in treating patients with multiple myeloma.
- Conditions
- Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
- Trial name
- NCT02353572
- Testing
- Melphalan, Bortezomib, Dexamethasone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Colorado, Denver
Myeloma
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
The goal of this clinical research study is to learn if the combination of gemcitabine, busulfan, and melphalan, when given before a stem cell transplant, can help to control refractory myeloma.
- Trial name
- NCT01237951
- Testing
- Palifermin, Dexamethasone, Gemcitabine
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant
This study will enroll myeloma subjects undergoing autotransplantation. The primary objective of this study is to evaluate whether infusions of Id-KLH primed CD3/CD28 activated autologous lymphocytes mediate a more intense…
- Trial name
- NCT01426828
- Testing
- CD3/CD28
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Graft-Versus-Host Disease
Tissue Repair in Stem Cell Transplant Recipients
Primary Objective: 1. To determine whether rhG-CSF treatment will increase the frequency of donor-derived cells contributing to repair of damaged epithelial/endothelial or solid organ-specific tissue caused by graft-versus-host…
- Trial name
- NCT00501228
- Testing
- Filgrastim
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.